The following industry-sponsored contracts have been received. Here is more information on clinical trials enrolling patients at UNMC.
James Gigantelli, M.D., ophthalmology and visual sciences, is the UNMC lead for a multi-center Phase III clinical trial to evaluate the safety and effectiveness of a novel protein therapy for the treatment of thyroid eye disease (TED).
Jue Wang, M.D., internal medicine – oncology/hematology, is the UNMC lead for a multi-center Phase I/II clinical trial to evaluate the safety and effectiveness of a small molecule inhibitor of a heat shock protein believed to support the growth and spread of many cancer cells. Patients with non-responsive prostate cancer will either receive the inhibitor in combination with existing chemotherapeutics or alone and evaluated for a reduction in tumor cell growth.
Pamela Carmines, Ph.D., cellular and integrative physiology, is evaluating the impact of ROMK (renal outer medullary K+ channels) on renal arteriole function. K+ channels may play a role in the changes in renal function found early in diabetes which lead to diabetic nephropathy and the eventual decline in renal function in diabetic patients.
Austin Thompson, M.D., internal medicine – pulmonary, is the UNMC lead for two multi-center clinical trials to evaluate the effectiveness of a new oral prostacyclin-like compound on the long-term outcome of patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.
Elizabeth Reed, M.D., internal medicine – oncology/hematology, is the UNMC lead for a multi-center Phase II clinical trial to evaluate the safety and effectiveness of adding an additional chemotherapeutic agent to current treatment for patients with HER2- breast cancer.
William Burke, M.D., psychiatry, is the UNMC lead for a multi-center Phase II clinical trial to evaluate an orally administered therapeutic agent for the treatment of Alzheimer’s disease on the safety and effectiveness in treating the symptoms of agitation and aggression in Alzheimer’s patients.
Julia Bridge, M.D., pathology and microbiology, is investigating the clinical specificity of a new molecular assay for the detection of bladder cancer.
Quan Dong Nguyen, M.D., ophthalmology and visual sciences, is the UNMC lead on a Phase I/II clinical trial to determine the safety and tolerability of a currently marketed anti-inflammatory agent for a new use in the treatment of patients with non-infectious uveitis.
Andre Kalil, M.D., internal medicine – infectious diseases, is the UNMC lead on a Phase III Clinical Trial to assess the safety and effectiveness of a recombinant human soluble thrombomodulin when used to treat complications of sepsis.
Debra Reilly, M.D., surgery – plastic & reconstructive surgery, is the UNMC collaborator for a study on injuries related to glass-fronted fireplaces.